Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical feedback from experience with COVID-19: Specific considerations for extracorporeal membrane oxygenation

A new viral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in the end of 2019 in China. Since then, the disease has expanded rapidly worldwide and the World Health Organization (WHO) has characterized the disease as coronavirus disease 2019 (COVID-19) and declared it as a pandemic on March 2020. Although the majority of COVID-19 patients are asymptomatic or paucisymptomatic, many patients can experience respiratory failure, and quickly progress to acute respiratory distress syndrome (ARDS) requiring advanced and rescue therapies.

SARS-CoV-2 is associated with very high mortality and is related to the direct and indirect effects of disease and to the lack of effective therapies. The role of ExtraCorporal Membrane Oxgenation (ECMO), as a rescue therapy in refractory hypoxemia during severe COVID-19, is currently not well defined, and only limited case series reporting a very high mortality rate are available. Results of the V-V ECMO therapy during influenza A (H1N1) and MERS outbreaks suggest that ECMO may be helpful in selected patients, so could it be in COVID-19 patients. Our experience is based on more of 50 COVID-19 patients treated with ECMO since March 2020 in our institution (Henri Mondor Hospital, a referral Ecmo center of the Paris network). Over more than 350 COVID-19 critically ill patients had managed in our ICU, we report some practical observations on the management of ECMO therapy in the severe COVID-19 cases (Fig. 1).

Technical considerations: cannulation site and size of cannulas

The V-V ECMO classic configuration with a double cannulation of the right internal jugular vein and the right femoral vein should be preferred; femoral-jugular configuration is the most efficient technique for respiratory support, especially in the most hypoxemic patients, and allows lower recirculation rate that femoro-femoral configuration. When the preferred cannulation is not possible, the alternative configurations of V-V ECMO support involve bilateral femoral cannulation or more rarely the use of left internal jugular vein.

So, at ICU admission, we recommend to preserve the right venous jugular access for further possible need for V-V ECMO, and to insert central venous catheter into the left internal jugular vein.

Oxygenation of the ECMO depends on the fraction of inspired oxygen (FiO2) in the gas mixture of oxygenator and principally on ECMO flow. So, V-V ECMO therapy requires a high flow rate approaching at least two thirds of patient’s cardiac output, a condition that necessitates use of large cannulas. This concept is even more valid for COVID-19 patients, for whom ECMO indication is more driven by hypoxemia than hypercapnia. In addition, as obesity is a clear risk factor for severe COVID-19 pneumonia, and as obese patients have higher cardiac output, high flow rates are required. To ensure maximal flow and avoid hemolysis, large caliber drainage cannulas relative to the presumed needs of the patient, typically 25 to 29 French should be used. On the contrary, percutaneous double lumen bicaval cannula should be avoided for COVID-19 patients, as high blood flows cannot be achieved with this technique.

Veno-Arterial ECMO and Harlequin syndrome

In some patients with COVID-19, shock can be present due to septic shock, cytokine storm, acute core pulmonary or specific cardiac failure with myocarditis, Takotsubo syndrome or coronary thrombosis enhanced by inflammation. In case of cardio- genic shock, alone or associated with ARDS, veno-arterial (V-A) ECMO support can be required. Less frequently, patients treated initially with V-V ECMO for respiratory failure may subsequently develop cardiac failure, requiring secondary V-A ECMO support. For instance, in our experience, 7 patients were supported with an initial VA-ECMO: in 4 cases, the initial indication was refractory ARDS, but hypoxic cardiac arrest occurred at the moment of cannulation, in 2 cases the indication was a pulmonary embolism and in 1 case severe myocarditis. In 1 case the initial V-V ECMO was changed in veno-arterio-venous (V-AV) ECMO for a right ventilar failure. All patients who experienced hypoxic cardiac arrest and one patient with pulmonary embolism developed differential cyanosis with upper body hypoxemia and lower body hyperoxia, resulting in a Harlequin syndrome. This syndrome, also defined as north-south syndrome, is a well-known complication of peripheral V-A ECMO and in COVID-19 patients must be suspected and recognized at an early stage.

Anticoagulation levels

Observations converge toward procoagulant patterns characterized by hypercoagulability and high rate of arterial/venous thrombosis. D-dimer levels, indeed, are high in most COVID-19 patients and have been associated with worse prognosis. These considerations are well correlated with clinical practice with a high rate of renal-replacement catheters thrombosis, or with the observation that during cannulae insertion for ECMO implantation, clots form early in the tubing. We revised our institutional protocols with higher targets of anticoagulation. Consequently, even though patients are already on therapeutic anticoagulant therapy, we suggest that a bolus with of 50 IU/kg unfractionated heparin should be administered, before cannulation. When a therapeutic anticoagulant therapy is not yet established, a double dose should be considered.

Anticoagulation monitoring during ECMO therapy is crucial to avoid thrombosis formation in the circuit, but at the same time to avoid haemorrhagic complications. In our experience, anti-Xa activity target should be increase to 0.5 and 0.7 IU/ml.
**PRACTICAL MANAGEMENT OF COVID-19 PATIENTS WITH ECMO**

**Fig. 1.** Schematic specific highlights of practical management of ECMO therapy in COVID-19 patients.

**Perspectives**

Due to the high virulence and severity of SARS-CoV-2, China, many countries have to cope with the massive arrival of patients in ICU. The limited resources of ventilators is one of the most important resource challenge, but at the same time, the availability of ECMO devices and circuits is also a challenge in the ECMO expert centers. A pooling of resources and the coordination of the various centers at regional and local level is a crucial point in the management of patients requiring ECMO. This organization has allowed the distribution of resources in the expert ECMO centers, but also the coordinated mobilization of ECMO teams towards non-specialized hospitals and the transfer of patients to expert ECMO center.

Despite the immense challenge, physicians have to face in the Covid-19 pandemic setting, research on ECMO is paramount importance to identify patients who will benefit the most, and the optimal management. Results of on-going registries and interventional studies are urgently requested.

**Declaration of Competing Interest**

None

**Acknowledgements**

We wish to thank all anesthesiologist, intensive care physicians, cardiac surgeons and perfusionist team for your collaboration.

**References**

1. World Health Organization (WHO). Coronavirus disease (COVID-19) outbreak [https://www.who.int], 2020.
2. Zeng Y, Cai Z, Xiang Y, Yang BX, Song T, Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care 2020 Apr 15;24(1):148.
3. Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care 2020 Apr 1;58:27–8.
4. Alshahrani MS, Sindl A, Alshami F, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care 2018;8:3.
5. Schmidt M, Zoghbi E, Rozé H, Repesse X, Lebreton G, Luyt CE, Trouillet JL, Bréchot N, Nieszkowska A, Dupont H, Ouattara A, Leprince P, Chastre J, Combes A. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med Oct 2013;39(10):1704–13 23907497.
6. Simonnet A, Chetboun M, Poissy J, Ravergy V, Noullette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain MLIntensive Care COVID-19 and Obesity study group High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020 Apr 9.
7. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020 Apr 18. 32317203.
8. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L. The propacogulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020 Apr 17.
9. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
10. Ramanathan K, Antognini D, Combes A, Paden M, Zakhar B, Ogino M, Maclaren G, Brodie D, Shekar K. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020 32213-2600:20:30121-1.

Antonio Fiore*

Service de chirurgie cardiaque, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France

Quentin de Roux, Nejla Daami, Simon Claricot
Service d’anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France

Thierry Folliguet
Service de chirurgie cardiaque, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France

Université Paris Est Créteil, Faculté de Santé, F-94010 Créteil, France

Fabio Silvio Taccone
Department of Intensive Care, Clinique Universitaire de Bruxelles (CUB) Erasme, Université Libre de Bruxelles, Bruxelles, Belgium

Nicolas Mongardon
Service d’anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France

Université Paris Est Créteil, Faculté de Santé, F-94010 Créteil, France

U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Créteil (UPEC), Ecole Nationale Vétérinaire d’Alfort (EnVA), F-94700 Maisons-Alfort, France

AfterROSC research group, F-75014 Paris, France

*Corresponding author. E-mail address: antonio.fiore@aphp.fr (A. Fiore)